Get started
Author

Hongying Wang

Observed name: H. F. Wang
ORCID: 0000-0002-3963-1155
Observed ORCID: 0000-0002-3963-1155
OpenAlex ID: A5046830483
LILRB4 on multiple myeloma cells promotes bone lesion by p-SHP2/NF-κB/RELT signal pathway
2024 · Hongying Wang, Lei Wang, et al. · Journal of Experimental & Clinical Cancer Research · 22
PDF
Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2023 · Yifan Liu, Hongying Wang, et al. · Cancer Research · 18
IGSF9-targeted therapy inhibits the progression of acute myeloid leukemia
2025 · Lijun Hui, Jing Xiao, et al. · Blood Advances · 5
PDF
Tumor-associated macrophages educated by IGSF9 exhibit a senescence-associated secretory phenotype to promote tumor immune escape
2026 · Jiasheng Zhang, Xianhui Meng, et al. · Journal for ImmunoTherapy of Cancer · 3
The Role of Soluble HLA-G in the Vertical Transmission of Toxoplasma gondii
2019 · H. F. Wang, Y. Z. Jiang, et al. · Molecular Biology · 2
Supplementary Data from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2023 · Yifan Liu, Hongying Wang, et al. · 1
Роль растворимого HLA-G при вертикальной передаче инфекции Toxoplasma gondii
2019 · H. F. Wang, Y. Z. Jiang, et al. · Molecular Biology · 1
Targeting immunoglobulin superfamily member 9 (IGSF9) to overcome acute myeloid leukemia resistance to CAR-T therapy
2026 · Xianhui Meng, Fangmin Li, et al. · Journal of Experimental & Clinical Cancer Research
Figure S2 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
Figure S3 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
PDF
Figure S1 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
PDF
Figure S4 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
Figure S6 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
PDF
Figure S7 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
Figure S5 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
Figure S8 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
PDF
Supplementary Data from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
PDF
Figure S8 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Supplementary Data from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Figure S6 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Figure S7 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Figure S3 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Figure S4 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Figure S5 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Figure S2 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Works count: 52
Citation count: 52
H-index: 3
I10-index: 2
Year
Topic
Type